| GeneLibs

题目:: MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.
作者:: Ryan(Bríd M),Calhoun(Kara M),Pine(Sharon R),Bowman(Elise D),Robles(Ana I),Ambs(Stefan),Harris(Curtis C)
状态:: 发布时间2012-09-26 , 更新时间 2016-11-25
期刊:: Int J Cancer
摘要:: Conflicting reports exist regarding the contribution of SNP309 in MDM2 to cancer risk. Recently, SNP285 was shown to act as an antagonist to SNP309 by overriding the effect of SNP309 on SP1-mediated transcription. Moreover, SNP285 modified the relationship between SNP309 and risk of breast, ovarian and endometrial cancer. We assessed whether SNP285 confounded the effect of SNP309 in lung cancer in a cohort of 720 controls and 556 cases. Our cohort included both Caucasians and African Americans. Neither SNP309 nor SNP285 was associated with lung cancer risk or survival. In addition, removal of individuals who carried the variant C allele of SNP285 did not modify the association between SNP309 with either lung cancer risk or survival. Although an effect of SNP285 has been demonstrated in breast, ovarian and endometrial cancer, our findings do not support a role for this SNP in lung cancer and raise the possibility that the effect of SNP285 is restricted to cancers in women.
语言:: eng
DOI:

文献库文献相关信息